Published Date: 02 Mar 2023
A study published online Feb. 27 in JAMA Internal Medicine found that interventions increase prevention but not the association with alcohol use disorder (AUD) in primary care.
Read Full NewsSusan Corbridge, PhD, and Alanna Kavannagh, MSN, CCRN, discuss the role of advanced practice providers on the evolving pulmonary and critical care teams during CHEST 2025.
The phase 3 study aims to confirm findings from the HEALEY ALS platform trial in patients with early-stage rapidly progressive ALS, which suggested potential benefits of pridopidine across multiple domains.
Holzem spoke in this interview about several additional highlights from her session at SDPA Fall regarding red flags in dermatology and when to admit from the clinic.
Key Skin Cancer Terms Not Understood by Almost 1/3 of Patients Surveyed
1.
Cancer tumor anatomy influences the benefits of chemotherapy for patients with early-stage breast cancer.
2.
Predicting adult mortality from oral cancer using a machine learning approach.
3.
What does it mean for Biden's prostate cancer to be 'aggressive'? A urologic surgeon explains
4.
Pediatric high-grade gliomas: Research reveals effective targeting with avapritinib
5.
Real World CAR T-Cell Therapy Outcomes 'Favorable' in Relapsed/Refractory Myeloma
1.
Mastering Modern Oncology: Accreditation, Education, and Research Trends for 2025
2.
The Ins and Outs of Glossectomy: What You Need to Know
3.
Targeting Oncology: Expanding Combinatorial Strategies by 2025
4.
Understanding the Importance of CA125: A Comprehensive Guide
5.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD
2.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
5.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation